PMID- 27649817
OWN - NLM
STAT- MEDLINE
DCOM- 20170223
LR  - 20181202
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 13
IP  - 1
DP  - 2017 Feb
TI  - Feasibility and kinetics of CD34(+) hematopoietic progenitor cell mobilization in 
      response to a single administration of docetaxel chemotherapy and pegfilgrastim 
      in a contemporary cohort of patients with metastatic breast cancer.
PG  - 79-86
LID - 10.1111/ajco.12601 [doi]
AB  - AIM: Autologous hematopoietic stem cell transplantation (auto-HSCT) remains an 
      experimental therapy for metastatic breast cancer (MBC) and there is no 
      established protocol for cluster of differentiation 34(+) (CD34(+) ) 
      hematopoietic progenitor cell (HPC) mobilization with historic studies using 
      growth factors with or without chemotherapy. This study describes the feasibility 
      and kinetics of CD34(+) HPC mobilization following a single administration of 
      docetaxel and the pegylated form of recombinant human granulocyte 
      colony-stimulating factor analogue filgrastim (pegfilgrastim). METHODS: The study 
      design was serial measurement of peripheral blood CD34(+) HPC in patients with 
      MBC following a single administration of intravenous (IV) docetaxel 100 mg/m(2) 
      on day 1 and subcutaneous (SC) pegfilgrastim 6 mg on day 2. RESULTS: Eight 
      patients with MBC were enrolled. The median age was 56 years (range 51-75 years). 
      All patients had human epidermal growth factor receptor 2 (HER2) negative disease 
      and either hormone refractory or negative disease. Three patients had bone only 
      disease, four had visceral organ disease with or without bone involvement and one 
      had locally unresectable disease only. All patients had prior therapy for 
      early-advanced stage disease and prior therapy for MBC included seven patients 
      receiving at least one line of hormone therapy and three having palliative 
      chemotherapy. Six patients recorded a rise in the CD34(+) count greater than 20 
      cells/muL. The median peak level was 40.2 cells/muL (standard deviation = 28.7) 
      occurring on day 9 and with an average duration of 4 days. Overall, treatment was 
      well tolerated with manageable side-effects. CONCLUSION: The single 
      administration of docetaxel and pegfilgrastim was effective in mobilization of 
      CD34(+) HPC and peak levels followed a predictable course. This approach needs 
      validation in prospective studies by preparation of auto-HSCT by leukapheresis 
      and quantification of total CD34(+) HPC yields.
CI  - (c) 2016 John Wiley & Sons Australia, Ltd.
FAU - Takhar, Harminder
AU  - Takhar H
AD  - Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
FAU - Mislang, Anna Rachelle
AU  - Mislang AR
AD  - Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
FAU - Singhal, Nimit
AU  - Singhal N
AD  - Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
FAU - Brown, Michael P
AU  - Brown MP
AD  - Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
AD  - Centre for Cancer Biology, SA Pathology and University of South Australia, 
      Adelaide, SA, Australia.
AD  - Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20160921
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Antigens, CD34)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Taxoids)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 15H5577CQD (Docetaxel)
RN  - 3A58010674 (pegfilgrastim)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - PVI5M0M1GW (Filgrastim)
SB  - IM
MH  - Aged
MH  - Antigens, CD34
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*drug therapy
MH  - Docetaxel
MH  - Feasibility Studies
MH  - Female
MH  - Filgrastim
MH  - Granulocyte Colony-Stimulating Factor/*therapeutic use
MH  - Hematopoietic Stem Cell Mobilization/*methods
MH  - Hematopoietic Stem Cell Transplantation/methods
MH  - Humans
MH  - Middle Aged
MH  - Polyethylene Glycols
MH  - Prospective Studies
MH  - Recombinant Proteins/therapeutic use
MH  - Taxoids/*therapeutic use
OTO - NOTNLM
OT  - *CD34
OT  - *antineoplastic agents
OT  - *breast neoplasms
OT  - *granulocyte colony-stimulating factor
OT  - *hematopoietic progenitor cell mobilization
EDAT- 2016/09/22 06:00
MHDA- 2017/02/24 06:00
CRDT- 2016/09/22 06:00
PHST- 2015/05/14 00:00 [received]
PHST- 2015/10/24 00:00 [revised]
PHST- 2016/01/13 00:00 [accepted]
PHST- 2016/09/22 06:00 [pubmed]
PHST- 2017/02/24 06:00 [medline]
PHST- 2016/09/22 06:00 [entrez]
AID - 10.1111/ajco.12601 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2017 Feb;13(1):79-86. doi: 10.1111/ajco.12601. Epub 2016 
      Sep 21.